Drug Trial Radar · NCT01376167
Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse
Last checked: Nov 19, 2026Latest source record: Apr 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
851
Actual
Start
Apr 24, 2014
Primary completion
Nov 18, 2016
Study completion Nov 18, 2016
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Medicines for Malaria Venture
- First posted
- Jun 20, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this two part study is to test the safety and efficacy of Tafenoquine (with Cholorquine) as a radical cure for Plasmodium vivax (P.vivax) malaria relative to the control Chloroquine.Part 1 aims to select an efficacious and well tolerated dose that can be co-administered with Chloroquine. Part 2 will investigate the safety and efficacy of the selected dose (300 mg tafenoquine) in the treatment and radical cure of Plasmodium Vivax Malaria.
Conditions
- Malaria, Vivax
Interventions
Chloroquine 600mgDrug
600mg Chloroquine given to each subject on Day 1 and Day2 of the trial
Chloroquine 300mgDrug
300mg Chloroquine given to each subject on Day 3 of the trial
Tafenoquine 50mgDrug
single dose 50mg Tafenoquine given to subject on treatment arm 1 on Days 1 or 2
Tafenoquine 100mgDrug
single dose 100mg Tafenoquine given to subject on treatment arm 2 on Days 1 or 2
Tafenoquine 300mgDrug
single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2
Tafenoquine 600mgDrug
single dose 600mg Tafenoquine given to subject on treatment arm 4 on Days 1 or 2
Primaquine 15mgDrug
15mg Primaquine given once daily to subject on treatment arm 5 on Days 2 to 15.
Chloroquine 600mg (Part 2 )Drug
600mg Chloroquine given to each subject on Day 1 and Day2 of the trial.
Chloroquine 300mg (Part 2 )Drug
300mg Chloroquine given to each subject on Day 3 of the trial.
Tafenoquine 300mg (Part 2)Drug
single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2.
Primaquine 15mg (Part2 )Drug
15mg Primaquine given once daily to subject on treatment arm 3 on Days 2 to 15.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Recurrence-free Efficacy at 6 Months Post DoseTime frame: 6 months post dose
Locations
14 sites in 8 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Bāndarban, Bangladesh
GSK Investigational Site
Manaus, Amazonas, Brazil
GSK Investigational Site
Porto Velho, Rondônia, Brazil
GSK Investigational Site
Oddar Meancheay Province, Cambodia
GSK Investigational Site
Gonder, Ethiopia
GSK Investigational Site
Jimma, Ethiopia
GSK Investigational Site
Bikaner, India
GSK Investigational Site
Chennai, India
GSK Investigational Site
Lucknow, India
GSK Investigational Site
Secunderabad, India
GSK Investigational Site
Iquitos, Loreto, Peru
GSK Investigational Site
Rio Tuba, Bataraza, Philippines
GSK Investigational Site
Bangkok, Thailand
GSK Investigational Site
Tak, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.